Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05233397 · ClinicalTrials.gov registry record · Phase 2
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
A Phase 2 study of Adamantinomatous Craniopharyngioma and Recurrent Adamantinomatous Craniopharyngioma, sponsored by Nationwide Children's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 12
- Study locations
NCT05233397 is a Phase 2 study of Adamantinomatous Craniopharyngioma and Recurrent Adamantinomatous Craniopharyngioma that is actively recruiting participants, run by Nationwide Children's Hospital. The registered enrollment target is 38 participants. The trial reports 12 study locations across 11 states.
The verdict
NCT05233397, a Phase 2 study of Adamantinomatous Craniopharyngioma and Recurrent Adamantinomatous Craniopharyngioma, is actively recruiting participants, sponsored by Nationwide Children's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 12
- Study locations
Study Summary
ACTEMRA (tocilizumab) is an IL-6 receptor antagonist used for the treatment of adult Rheumatoid Arthritis as well as Polyarticular (PJIA) and Systemic (SJIA) Juvenile Idiopathic Arthritis. In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.
Conditions Studied
Interventions
- DRUG Tocilizumab
Study Locations (12)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Florida
- Nicklaus Children's Hospital - Miami
North Carolina
- Duke Children's Hospital - Durham
Texas
- Texas Children's Hospital - Houston
Washington
- Seattle Children's Hospital - Seattle
New South Wales
- Sydney Children's Hospital - Randwick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2022-12-16 |
| Est. Completion | 2029-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05233397
The ClinicalTrials.gov registry entry for NCT05233397 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Adamantinomatous Craniopharyngioma appearing as the primary indexed condition, and to 1 intervention - of which Tocilizumab is the first listed.
NCT05233397 reports 12 study locations spanning 11 distinct geographic areas - top geographies include Ohio, Colorado, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05233397 about?
NCT05233397 is a clinical study titled "ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma". ACTEMRA (tocilizumab) is an IL-6 receptor antagonist used for the treatment of adult Rheumatoid Arthritis as well as Polyarticular (PJIA) and Systemic (SJIA) Juvenile Idiopathic Arthritis. In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous C...
What is the current status of trial NCT05233397?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2022-12-16. Estimated completion is 2029-12.
What conditions does trial NCT05233397 study?
This clinical trial studies the following conditions: Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma.
What interventions are being tested in trial NCT05233397?
The interventions under investigation include: Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT05233397?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05233397 being conducted?
This trial has 12 study locations across Colorado, District of Columbia, Florida, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adamantinomatous Craniopharyngioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Adamantinomatous Craniopharyngioma
All registered trials for this condition
Recurrent Adamantinomatous Craniopharyngioma
All registered trials for this condition
Colorado
All trials with a study site in Colorado
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.